[go: up one dir, main page]

HK1148435A1 - 治療糖尿病的氧雜二氮雜蒽化合物 - Google Patents

治療糖尿病的氧雜二氮雜蒽化合物

Info

Publication number
HK1148435A1
HK1148435A1 HK11102525.7A HK11102525A HK1148435A1 HK 1148435 A1 HK1148435 A1 HK 1148435A1 HK 11102525 A HK11102525 A HK 11102525A HK 1148435 A1 HK1148435 A1 HK 1148435A1
Authority
HK
Hong Kong
Prior art keywords
oxadiazoanthracene
diabetes
compounds
treatment
oxadiazoanthracene compounds
Prior art date
Application number
HK11102525.7A
Other languages
English (en)
Inventor
‧米加裡
‧波裡塞蒂
‧約庫姆
‧桑托什
‧居澤爾
‧貝梅
‧戴維斯
Original Assignee
轉化技術製藥有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 轉化技術製藥有限責任公司 filed Critical 轉化技術製藥有限責任公司
Publication of HK1148435A1 publication Critical patent/HK1148435A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK11102525.7A 2008-03-07 2011-03-14 治療糖尿病的氧雜二氮雜蒽化合物 HK1148435A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3459908P 2008-03-07 2008-03-07
PCT/US2009/036333 WO2009111700A2 (en) 2008-03-07 2009-03-06 Oxadiazoanthracene compounds for the treatment of diabetes

Publications (1)

Publication Number Publication Date
HK1148435A1 true HK1148435A1 (zh) 2011-09-09

Family

ID=41056666

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11102525.7A HK1148435A1 (zh) 2008-03-07 2011-03-14 治療糖尿病的氧雜二氮雜蒽化合物

Country Status (18)

Country Link
US (7) US7727983B2 (zh)
EP (1) EP2262364B1 (zh)
JP (1) JP5382952B2 (zh)
KR (1) KR101616737B1 (zh)
CN (1) CN101959405B (zh)
AU (1) AU2009221722B2 (zh)
BR (1) BRPI0910282A2 (zh)
CA (1) CA2716664C (zh)
DK (1) DK2262364T3 (zh)
EA (1) EA018225B1 (zh)
ES (1) ES2567451T3 (zh)
HK (1) HK1148435A1 (zh)
IL (1) IL207570A (zh)
MA (1) MA32175B1 (zh)
MX (1) MX2010009752A (zh)
NZ (1) NZ587343A (zh)
WO (1) WO2009111700A2 (zh)
ZA (1) ZA201006367B (zh)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ587343A (en) * 2008-03-07 2012-05-25 Transtech Pharma Inc Oxadiazoanthracene compounds for the treatment of diabetes
MX2011010347A (es) 2009-03-30 2011-11-29 Transtech Pharma Inc Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
RU2013127611A (ru) 2010-12-23 2015-01-27 Пфайзер Инк. Модуляторы глюкагонового рецептора
WO2012096824A1 (en) * 2011-01-12 2012-07-19 Transtech Pharma, Inc. Phenylglyoxylic acid derivatives and their preparation and use
JP5562495B2 (ja) 2011-02-08 2014-07-30 ファイザー・インク グルカゴン受容体モジュレーター
WO2013014569A1 (en) 2011-07-22 2013-01-31 Pfizer Inc. Quinolinyl glucagon receptor modulators
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
NZ629203A (en) * 2012-03-22 2015-12-24 Vtv Therapeutics Llc Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof
EP2911655A1 (en) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
ES2687083T3 (es) * 2013-01-17 2018-10-23 Vtv Therapeutics Llc Combinaciones de un agonista del GLPR1 y metformina y el uso de estos para el tratamiento de la diabetes tipo 2 y otros trastornos
EA032525B1 (ru) * 2014-07-25 2019-06-28 Селджин Интернэшнл Ii Сарл Модуляторы рецептора glp-1
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
TW201925204A (zh) * 2017-11-22 2019-07-01 日商第一三共股份有限公司 稠合三環化合物
MX2020008387A (es) 2018-05-08 2020-12-11 Vtv Therapeutics Llc Usos terapeuticos de agonistas glp1r.
PH12021552557A1 (en) 2019-04-12 2022-07-04 Qilu Regor Therapeutics Inc Glp-1r agonists and uses thereof
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
EP4159737A4 (en) * 2020-05-28 2024-10-09 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. METHOD FOR PREPARING A GLP-1 RECEPTOR AGONIST-FREE BASE
EP4159719A4 (en) * 2020-05-28 2024-07-17 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Preparation method for (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)methyl propionate diacid salt
WO2022007979A1 (zh) 2020-09-01 2022-01-13 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
EP4227299A1 (en) 2020-10-12 2023-08-16 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Benzimidazolone glp-1 receptor agonist and use thereof
US20240246959A1 (en) 2020-11-27 2024-07-25 Shenzhen Salubris Pharmaceuticals Co., Ltd. Benzimidazole derivative and preparation method therefor and medical use thereof
US20240208952A1 (en) 2021-03-22 2024-06-27 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Thiophene glp-1 receptor agonist and use thereof
JPWO2022202864A1 (zh) 2021-03-24 2022-09-29
CN117500808A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
EP4361145A1 (en) 2021-06-24 2024-05-01 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Glp-1 receptor agonist and composition and use thereof
CN115521320B (zh) * 2021-06-25 2023-09-05 沈阳兴齐眼药股份有限公司 一种制备普拉洛芬的方法
WO2024063143A1 (ja) 2022-09-22 2024-03-28 塩野義製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を有する縮合環化合物
US12234236B1 (en) 2023-09-14 2025-02-25 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233728A1 (en) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. 1,4-Benzoxazine derivatives their production and use
JPS6345270A (ja) * 1986-02-11 1988-02-26 Takeda Chem Ind Ltd １，４−ベンゾオキサジン誘導体，その製造法およびそれを含有する医薬用組成物
JP2002515025A (ja) * 1995-10-06 2002-05-21 リガンド・ファーマシューティカルズ・インコーポレイテッド ダイマー選択的ｒｘｒモジュレーターおよびその使用方法
JP2002534512A (ja) * 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
WO2001040192A1 (fr) * 1999-12-03 2001-06-07 Kyoto Pharmaceutical Industries, Ltd. Nouveaux composes heterocycliques et sels de ces derniers, utilisations de ces composes en medecine
EP1125925A1 (en) * 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
US20050222036A1 (en) * 2000-08-24 2005-10-06 Thomas Jefferson University Peptide compositions with effects on blood glucose
CA2518945A1 (en) * 2003-03-26 2004-10-07 Actelion Pharmaceuticals Ltd. Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
NZ587343A (en) * 2008-03-07 2012-05-25 Transtech Pharma Inc Oxadiazoanthracene compounds for the treatment of diabetes
JP2013530963A (ja) 2010-06-09 2013-08-01 レセプトス インコーポレイテッド 新規のｇｌｐ−１受容体安定化薬および調節薬

Also Published As

Publication number Publication date
US20150087640A1 (en) 2015-03-26
US9120813B2 (en) 2015-09-01
ZA201006367B (en) 2011-05-25
WO2009111700A3 (en) 2010-03-04
US20100324033A1 (en) 2010-12-23
IL207570A0 (en) 2010-12-30
MX2010009752A (es) 2010-09-30
MA32175B1 (fr) 2011-03-01
KR101616737B1 (ko) 2016-05-02
US20110039837A1 (en) 2011-02-17
NZ587343A (en) 2012-05-25
US20100197677A1 (en) 2010-08-05
JP2011513431A (ja) 2011-04-28
US20140187769A1 (en) 2014-07-03
US7906507B2 (en) 2011-03-15
CA2716664C (en) 2016-10-11
AU2009221722B2 (en) 2014-12-18
EP2262364B1 (en) 2016-03-02
CN101959405A (zh) 2011-01-26
AU2009221722A1 (en) 2009-09-11
EP2262364A4 (en) 2012-04-04
KR20100131455A (ko) 2010-12-15
US7727983B2 (en) 2010-06-01
CN101959405B (zh) 2014-07-02
US20090306063A1 (en) 2009-12-10
US7790714B2 (en) 2010-09-07
US8933222B2 (en) 2015-01-13
US8524708B2 (en) 2013-09-03
JP5382952B2 (ja) 2014-01-08
EA018225B1 (ru) 2013-06-28
IL207570A (en) 2014-03-31
EP2262364A2 (en) 2010-12-22
WO2009111700A2 (en) 2009-09-11
DK2262364T3 (en) 2016-03-21
CA2716664A1 (en) 2009-09-11
BRPI0910282A2 (pt) 2015-09-01
US8703766B2 (en) 2014-04-22
US20130317015A1 (en) 2013-11-28
ES2567451T3 (es) 2016-04-22
EA201071045A1 (ru) 2011-02-28

Similar Documents

Publication Publication Date Title
HK1148435A1 (zh) 治療糖尿病的氧雜二氮雜蒽化合物
ZA200902374B (en) Compositions useful for the treatment of diabetes
IL259475A (en) Combined therapy for the treatment of diabetes
ZA201105720B (en) Compounds for the treatment of hepatitis c
LT2303021T (lt) Junginiai, skirti vėžio gydymui
ZA200906129B (en) Compounds for the treatment of hepatitis c
IL209895A0 (en) Compounds for treating beta-amyloidoses
IL207520A0 (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
GB0806794D0 (en) Therapeutic compounds
GB0813740D0 (en) Therapeutic compounds
PL2209784T3 (pl) Związki do leczenia zapalenia wątroby typu C
ZA201000923B (en) Compounds for the treatment of hepatitis c
GB0804755D0 (en) Therapeutic compounds
IL211189A0 (en) Compounds for the treatment of peripheral neuropathies
IL211267A0 (en) Oxadiazole derivatives for the treatment of diabetes
EP2331099A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DIABETES MELLITUS
EP2240024A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
GB0817857D0 (en) Compounds for the treatment of neoplasia
GB0819536D0 (en) Compounds for the treatment of neoplasia
GB0802903D0 (en) Treatment of diabetes
GB0814997D0 (en) Processes for the preparation of compounds
GB0809319D0 (en) The treatment of puritus
GB0811850D0 (en) Therapeutic compounds
GB0816707D0 (en) Therapeutic compounds
GB0821817D0 (en) Therapeutic compounds